A multicenter, randomized placebo controlled pilot microCT study to estimate the effect of treatment with denosumab (AMG 162) and alendronate sodium in postmenopausal women with low bone mineral density.

Trial Profile

A multicenter, randomized placebo controlled pilot microCT study to estimate the effect of treatment with denosumab (AMG 162) and alendronate sodium in postmenopausal women with low bone mineral density.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Denosumab (Primary) ; Alendronic acid
  • Indications Bone resorption; Fracture; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 02 Apr 2014 Results comparing trabecular bone score and bone mineral density presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 08 Oct 2013 Results assessing bone measures at the lumbar spine, including the trabecular bone score, presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
    • 16 Oct 2012 Results assessing effects of treatment on trabecular bone volume fraction and intracortical porosity presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top